0001193125-26-212128
SEC filingIN8bio reported Q1 2026 financial results with $21.9M cash, net loss of $5.1M, approved the Amended and Restated 2026 Equity Incentive Plan, and elected Class II directors at its annual meeting.
IN8bio's Q1 2026 results showed a narrowed net loss to $5.1 million from $5.6 million year-over-year, driven by lower R&D expenses from reduced INB-400 clinical activity, while G&A remained stable at $2.7 million. Cash increased to $21.9 million from $11.9 million prior year, supporting ongoing operations amid pipeline advancement. The press release highlighted strong GBM data with 97% mPFS improvement (13.0 vs 6.6 months SOC) and immature mOS of 17.2+ months, with updates at ASCO 2026, and progress on INB-619 TCE platform targeting CD19 with minimal CRS cytokines, expecting animal data in 2026. At the annual meeting, stockholders approved the 2026 Plan, increasing shares by 2,920,000 to a 4,054,937 reserve, setting ISO max at 20M shares, and extending annual 5% increases through 2037, including pre-funded warrants in the calculation. Directors Brandt and Epperly were elected with strong support, and CohnReznick ratified as auditors. These approvals enhance equity compensation flexibility to retain talent amid clinical milestones like FDA GBM guidance and INB-100 follow-up in 2H26.